07/08/2023Published by Fondazione Gianni Bonadonna at 07/08/2023Categories Events UncategorizedDeterminants of trastuzumab deruxtecan response in metastatic breast cancer
31/07/2023Published by Fondazione Gianni Bonadonna at 31/07/2023Categories Events UncategorizedA new FGFR2 inhibitor with activity across FGFR2 alterations
24/07/2023Published by Fondazione Gianni Bonadonna at 24/07/2023Categories Events UncategorizedCabozantinib, nivolumab and ipilimumab in advanced renal-cell carcinoma
17/07/2023Published by Fondazione Gianni Bonadonna at 17/07/2023Categories Events UncategorizedTrifluridine-tipiracil plus bevacizumab in metastatic colorectal cancer
10/07/2023Published by Fondazione Gianni Bonadonna at 10/07/2023Categories Events UncategorizedTargeting an unexpected vulnerability p53-inactivated triple negative breast cancer
03/07/2023Published by Fondazione Gianni Bonadonna at 03/07/2023Categories Events UncategorizedActivity of tucatinib plus trastuzumab in metastatic colorectal cancer
26/06/2023Published by Fondazione Gianni Bonadonna at 26/06/2023Categories Events UncategorizedTrastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: results from DESTINY-Breast02
19/06/2023Published by Fondazione Gianni Bonadonna at 19/06/2023Categories Events UncategorizedA way to overcome resistance to FGFR therapy in cholangiocarcinoma
12/06/2023Published by Fondazione Gianni Bonadonna at 12/06/2023Categories Events UncategorizedCo-mutations effects on KRAS G12C inhibitor efficacy in advanced non-small cell lung cancer
